On April 21, 2021 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, reported that it has commenced an underwritten public offering of shares of common stock (Press release, NeuBase Therapeutics, APR 21, 2021, View Source [SID1234578365]). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, NeuBase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by NeuBase.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RBC Capital Markets, Oppenheimer & Co. Inc. and Chardan are acting as the joint book-running managers for the offering, and National Securities Corp. is acting as a co-manager.

NeuBase intends to use the net proceeds from the offering for general corporate purposes, working capital and development of its product candidates and pipeline expansion.

The securities described above will be offered by NeuBase pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-254980) previously filed with the Securities and Exchange Commission (the "SEC") on April 1, 2021 and declared effective by the SEC on April 14, 2021. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC’s website at www.sec.gov or by contacting RBC Capital Markets, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by e-mail at [email protected], Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055 or by e-mail at [email protected], or Chardan, 17 State Street, 21st floor, New York, New York 10004, by telephone at (646) 465-9032 or by e-mail at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On April 21, 2021 PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras) (Press release, PerkinElmer, APR 21, 2021, View Source [SID1234578345]). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shredding capabilities.

To help in these efforts, PerkinElmer will provide the consortium with no-wash AlphaLISA and HTRF immunoassay technologies and expertise in protein labeling as well as assay design; EnVision multimode plate readers; high content imaging technologies such as the Opera Phenix and Operetta CLS platforms; and data analysis and informatics tools like TIBCO Spotfire software. These PerkinElmer offerings will give PROXIDRUGS scientists a highly sensitive and accelerated discovery platform with rich data delivery and high throughput for both live and dead cell research.

Commenting on this groundbreaking research and collaboration, Alan Fletcher, SVP of Life Sciences at PerkinElmer said, "With only 20% of disease-relevant proteins currently being targeted by classical, small molecule drugs, new research approaches, such as PROTAC drug discovery, hold immense and exciting potential. We are delighted to be able to contribute our expertise and technologies to assist in the innovative work of the PROXIDRUGS Consortium as it seeks new ways to help unlock and tackle the vast majority of proteins behind widespread diseases such as cancer, neurological disorders, and cardiovascular, inflammatory and infectious conditions."

The PROXIDRUGS consortium is led by Ivan Đikić of Goethe University Frankfurt who also commented on the importance of forming alliances across organizations to help advance novel drug discovery and development, "Successful translation of biomedical research requires strong collaboration and convergence of industry and academic expertise. Our work with PerkinElmer within the PROXIDRUGS consortium is a good example of that. PerkinElmer’s expertise and innovation in assay development is of utmost importance and will help to create new insights for our discovery efforts."

The PROXIDRUGS Consortium was recently selected for funding by the German Federal Ministry of Education and Research as part of a highly competitive "Clusters4Future" competition.

On April 21, 2021 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, reported a preclinical collaboration with researcher Jay Gertz, Ph.D., to examine the potential effects of lasofoxifene, Sermonix’s lead investigational drug, on endometrial cancer (Press release, Sermonix Pharmaceuticals, APR 21, 2021, View Source [SID1234578341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The project will investigate the effects of lasofoxifene on unique models of endometrial cancer that carry ESR1 mutations. Lasofoxifene has shown novel activity in ESR1 mutations, and Sermonix is currently enrolling patients in two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies within the breast cancer arena.

"Sermonix is committed to exploring ESR1 mutations across gynecological tumor types and examining lasofoxifene’s potential to serve the unmet medical needs of more women fighting cancer," said Barry Komm, Ph.D., chief scientific officer of Sermonix. "The unique ESR1 model system is state-of-the-art for this exploration and Dr. Gertz is an esteemed partner with whom it is an honor for Sermonix to collaborate."

Dr. Gertz is a cancer researcher at Huntsman Cancer Institute and associate professor of oncological sciences at the University of Utah. His lab studies how transcription regulation is altered in cancer with a particular focus on the roles of steroid hormone signaling in endometrial and breast cancers.

"The Gertz Lab has a major emphasis in advancing the study of new drugs for endometrial cancer, an aggressive disease with limited treatment options," said Dr. Gertz. "We look forward to learning more about the efficacy of lasofoxifene in the context of ESR1-mutated endometrial cancer."

About Lasofoxifene
Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.

On April 21, 2021 Hamlet Pharma reported that the report of the phase I/II bladder cancer trial has been accepted for publication in Nature Communications; a leading international journal (Press release, HAMLET Pharma, APR 21, 2021, View Source;utm_medium=rss&utm_campaign=bladder-cancer-study-results-accepted-for-publication-in-nature-communications [SID1234578330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper is entitled "Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex" and has been accepted for publication in Nature Communications. The Nature journals are extremely competitive and only accept innovative science of highest quality and with significant interest for a discerning audience. The journals are widely read, with a high impact.

The paper analyses the structure of the Alpha1H complex, characterizes its tumor killing effects and describes the successful clinical trial of Alpha1H in patients with bladder cancer. A detailed analysis of primary and secondary end points is provided and differences between the Alpha1H treated patients and the placebo group are described for several crucial efficacy variables. Alpha1H triggered significant shedding of tumor cells in patients, who received the treatment (p< 0.0001 compared to the placebo group) and reduced the tumor size (p<0.04), illustrating its potent effects.

The treatment is also shown to be safe, as no drug-related side effects were observed. The publication offers interested readers a detailed understanding of the molecular properties and promising clinical effects, inspiring further development of Alpha 1H as a new potential drug for patients with bladder cancer.

"Publishing in Nature journals is an important quality stamp and an excellent way to spread the news of our clinical advances" says Catharina Svanborg, founder, CMO and chairman of the board of Hamlet Pharma Ltd.

"This is a very important milestone, inspriring us to continue the clinical development of Alpha1H with full speed" says Mats Persson, CEO of Hamlet Pharma Ltd.

On April 21, 2021 Each quarter, Locust Walk reported compile key statistics and trends on strategic transactions and financings (Press release, Locust Walk Partners, APR 21, 2021, https://www.locustwalk.com/q1-market-conditions-report-2021/?utm_source=rss&utm_medium=rss&utm_campaign=q1-market-conditions-report-2021 [SID1234578329]). Our 2021 Q1 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal landscape. 2020 was a record year for financings across the globe and that trend continued into Q1 2021 for public and private financings alike. With a red hot capital markets environment, we’ve pondered whether or not the traditional route of early stage collaborations will remain as a mainstay for high-growth biotechs in the near-term. Join us for a webinar as we have an open discussion about that topic. We look forward to following the trend lines in Q2. A few more key insights across geographies in Q1 2021:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United States

Biotech indices underperformed the broader markets in Q1, likely over concerns around potential drug pricing reform and movement out of biotech and into "reopening" stocks
The US biopharma IPO momentum of 2020 carried into the first quarter of 2021, surpassing Q3 and Q4 2020 in both deal volume and aggregate value and with new IPOs outpacing the performance of key biotech indices
Total biotech SPAC IPO values reached nearly $2B in Q1 suggesting the SPAC trend is not slowing down. Multiple sponsor firms have backed 2nd SPACs prior to completion of their target acquisition from their first
Public and private financing activity remains notably robust, as companies seek to take advantage of the open IPO window and growing interest from private investors
Q1 closed out a record quarter for private financings, and 2019/2020 biopharma IPOs continue to perform well in the public markets, suggesting investors are bullish long-term on new biopharma opportunities
Strong deal flow among both licensing and M&A deals demonstrate sustained interest in strategic transactions despite dwindling total deal values
Europe

Vaccines, albeit with significant logistical hurdles, bring hope to recovering the "old normal" in the European Union at the end of this year. Throughout Q1 2021, Moderna’s, AstraZeneca’s and Janssen’s COVID-19 vaccines were approved by the EMA
Private financing in European biopharma companies keeps with last year’s uninterrupted growth trend, amounting a total of ~$1.4B in Q1 2021
European biopharma IPOs had a great year start as well, with 4 IPOs over $100M on the Nasdaq and several smaller IPOs on other global exchanges. In contrast, only one IPO took place in Q4 2020
European licensing deals saw a slight increase in deal value in Q1 2020, while M&As significantly decreased in Q1 with only 3 completed deals
Japan

The Japanese stock market is off to a bullish start in 2021, as the Nikkei 225 Index reached the 30,000 mark for the first time in over 30 years
The pharma and biotech sector had a strong performance in Q1 2021 alone (+8% and +16%, respectively), but overall growth of the two sectors since the beginning of 2020 is below market
The volume of deals in 2021 is at the similar pace as 2020, largely due to a dominant quarter by Takeda, who struck 6 deals including 2 over $1B in total deal size
Following a strong year in venture financing in 2020, Q1 2021 was even stronger: 8 deals with aggregate value of $67M which is more than double the value in Q1 2020
China

Slow quarter for the Chinese stock market, as the SSE Composite Index was down 1.7% in Q1 2021 and average share price of top Chinese pharma companies was flat for the second consecutive quarter
In-licensing deal volume in 2021 is similar as Q1 the previous year, but with larger value: 22 in-licensing deals were closed including 20 deals with over $50M in total deal size and 15 with over $5M upfront payment
Out-licensing activities continues in 2021, including 2 deals over $1B, both of which involving anti-PD-1 antibodies
Venture financing for biotech companies continue to exceed previous levels, as 47 companies raised capital for an aggregate total of $3B in Q1 alone, already surpassing full year values in 2018 and 2019
Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and life science companies.

Capabilities: cohesive strategy, market analytics, and transaction capabilities
Geographies: global footprint across all key life science geographies
Deal process: one globally-integrated team focused on your entire deal process from strategy through execution​